The Food and Drug Administration granted Sarepta an accelerated review for its Duchenne gene therapy drug, SRP-9001. Three of Sarepta’s previous Duchenne drugs went through the agency’s accelerated approval pathway, though this would be the first gene therapy. (Endpoints News)

Axsome Therapeutics announced that its Alzheimer’s agitation therapy, AXS-05, met a primary goal of delaying relapse time, as well as preventing relapse, in patients. AXS-05 is a combo therapy of dextromethorphan and a generic of Wellbutrin, a depression treatment. (STAT News)

AstraZeneca signed a licensing deal with C4X Discovery for $402 million to develop an oral therapy for inflammatory and respiratory diseases. The deal will allow AstraZeneca to use C4X’s NRF2 activator program. (Reuters)

CinCor Pharma’s hypertension drug baxdrostat didn’t meet its primary endpoint in a Phase II trial, with shares dropping 34%. However, a subgroup analysis of non-Hispanic patients found a reduction in blood pressure, and the results give the company a “better understanding which patients respond best to baxdrostat,” CEO Marc de Garidel said. (MarketWatch)

Organ donations increased during huge motorcycle rallies, a Harvard study found. Researchers see this finding as a call to action – first, to increase public safety, and, second, to improve education about organ donation in communities where the rallies are held, so that more of these unfortunate deaths can result in saving others’ lives. (The Boston Globe)